Investment Highlights

1. Established biopharmaceutical company with a global presence

•   Asset-light business model with significant growth potential

•   Strong experience in bringing products to market

2. Innovative technology platform Marinosolv® focused on allergy and eye diseases

•   Budesolv for allergic rhinitis Phase III study completed

•   Tacrosolv for multiple indications prior to Phase II study

•   Potential for additional indications through proprietary programs and/or pharma licensing deals

3. Carragelose®: an OTC platform specifically for the treatment of respiratory diseases

•   Six products on the market, distributed in more than 40 countries

•   Significant growth potential with additional near term (new) products launches in major markets

4. Experienced leadership team backed by high quality boards

•   Strong track record in the pharmaceutical industry and science community

•   Backed by an internationally renowned Scientific Advisory Board